Bahlawane, 2016 - Google Patents
Insights into ligand stimulation effects on gastro-intestinal stromal tumors signalling Christelle Bahlawane, Martine Schmitz, Elisabeth Letellier, Karthik Arumugam b …Bahlawane, 2016
View PDF- Document ID
- 9695429609179809142
- Author
- Bahlawane C
- Publication year
External Links
Snippet
Mutations in KIT or PDGFRA are responsible for more than 85% of gastrointestinal stromal tumors. The introduction of imatinib in the GIST therapy scheme revolutionized the patient outcome. Unfortunately, the therapy allows the disease stabilization instead of curation …
- 201000011243 gastrointestinal stromal tumor 0 title abstract description 96
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ro et al. | Tumor suppressive role of sestrin2 during colitis and colon carcinogenesis | |
| US20190127805A1 (en) | Gene signatures for cancer detection and treatment | |
| US20080234138A1 (en) | TP53 gene expression and uses thereof | |
| WO2014017491A1 (en) | Fusion gene of cep55 gene and ret gene | |
| WO2019083971A1 (en) | Methods of treating cancer using lsd1 inhibitors in combination with immunotherapy | |
| US20150265587A1 (en) | Androgen receptor variants and methods for making and using | |
| JP2015109806A (en) | Method for detecting new ret fused body | |
| US20250108050A1 (en) | Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer | |
| Yagil et al. | Transcription factor E3, a major regulator of mast cell–mediated allergic response | |
| Bylicki et al. | Targeting the MET-signaling pathway in non-small–cell lung cancer: Evidence to date | |
| JP6612232B2 (en) | Gene expression signatures for predicting responsiveness to multikinase inhibitors of interest, and uses thereof | |
| US20230048706A1 (en) | Compositions and methods for the diagnosis and treatment of lymphatic system disorders | |
| US20090232813A1 (en) | Four-Jointed Box (FJX1) In Cancer Diagnosis and Treatment | |
| US20220288067A1 (en) | Treatment of cancer with cdk inhibitors | |
| CN109675040B (en) | Composition for treating breast cancer and application thereof | |
| WO2020143424A1 (en) | Gastrointestinal stromal tumor target depdc5 and application thereof in diagnosis and treatment | |
| Bahlawane et al. | Insights into ligand stimulation effects on gastro-intestinal stromal tumors signalling | |
| Bahlawane | Insights into ligand stimulation effects on gastro-intestinal stromal tumors signalling Christelle Bahlawane, Martine Schmitz, Elisabeth Letellier, Karthik Arumugam b, Nathalie Nicot c, Petr V. Nazarov c and Serge Haan Molecular Disease Mechanisms group, Life Sciences Research Unit, University | |
| CN111617247A (en) | Use of epidermal growth factor receptor kinase substrate class 8 protein 3 in enhancing the efficacy of multi-targeted kinase inhibitors | |
| WO2011040954A2 (en) | Tp53 gene expression and uses thereof | |
| WO2012034076A2 (en) | Etv1 as a diagnostic, prognostic and therapeutic target for gastrointestinal stromal tumors | |
| Caswell et al. | The role of APOBEC3B in lung tumour evolution and targeted therapy resistance | |
| US20230323463A1 (en) | Compositions and methods for detecting bcl2l14 and etv6 gene fusions for determining increased drug resistance | |
| Moy | Differential Alternative Splicing of a Novel FGFR3 Variant Involved in African American Prostate Cancer Disparities | |
| WO2023166128A1 (en) | SEPARATION-OF-FUNCTION IKBα MUTANTS |